187 related articles for article (PubMed ID: 29065786)
1. Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline.
Osorio S; Escudero-Vilaplana V; Reguilón-Gallego L; Gómez-Centurión I; Díez JL; Ferrer-Marín F
J Oncol Pharm Pract; 2017 Jan; ():1078155217735689. PubMed ID: 29065786
[TBL] [Abstract][Full Text] [Related]
2. Novel Score-based Decision Approach in Chronic Myeloid Leukemia Patients After Acute Toxic Imatinib-induced Liver Injury.
Lopina N; Dmytrenko I; Hamov D; Lopin D; Dyagil I
Cureus; 2019 Apr; 11(4):e4411. PubMed ID: 31245199
[TBL] [Abstract][Full Text] [Related]
3. Acute pancreatitis in a patient treated with imatinib and gefitinib.
Escudero-Vilaplana V; Collado-Borrell R; Villanueva-Bueno C; Álvarez R; Herranz A; Sanjurjo M
J Oncol Pharm Pract; 2021 Jun; 27(4):980-983. PubMed ID: 32799779
[TBL] [Abstract][Full Text] [Related]
4. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.
Bilgi N; Bell K; Ananthakrishnan AN; Atallah E
Ann Pharmacother; 2010 May; 44(5):926-8. PubMed ID: 20332334
[TBL] [Abstract][Full Text] [Related]
5. Imatinib-induced fatal acute liver failure.
Ridruejo E; Cacchione R; Villamil AG; Marciano S; Gadano AC; Mandó OG
World J Gastroenterol; 2007 Dec; 13(48):6608-111. PubMed ID: 18161937
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.
Tonyali O; Coskun U; Yildiz R; Karakan T; Demirci U; Akyurek N; Benekli M; Buyukberber S
Med Oncol; 2010 Sep; 27(3):768-73. PubMed ID: 19662540
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate-induced acute hepatotoxicity.
Frikha I; Fakhfakh Y; Sahnoun R; Chtourou L; Medhaffar M; Elloumi M
J Oncol Pharm Pract; 2023 Dec; 29(8):2027-2030. PubMed ID: 37464887
[TBL] [Abstract][Full Text] [Related]
8. Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.
Morán VP; Baute RG; Facundo JC; Ramírez PH; Núñez AA; Martínez EE; Cabrera OM; Padrón CH; Otero AG; Uría JC; Estrada EE; Díaz RM; Virgil AM; Sánchez KL; Cabeza AH
MEDICC Rev; 2011 Jan; 13(1):35-40. PubMed ID: 21273957
[TBL] [Abstract][Full Text] [Related]
9. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.
Harbaum L; Marx A; Goekkurt E; Schafhausen P; Atanackovic D
Int J Hematol; 2014 Jan; 99(1):91-4. PubMed ID: 24264834
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study.
Matti BF; Alwan AF; Alwan AF
Turk J Haematol; 2013 Dec; 30(4):387-93. PubMed ID: 24385829
[TBL] [Abstract][Full Text] [Related]
11. Sertraline hepatotoxicity: report of a case and review of the literature.
Tabak F; Gunduz F; Tahan V; Tabak O; Ozaras R
Dig Dis Sci; 2009 Jul; 54(7):1589-91. PubMed ID: 18958618
[TBL] [Abstract][Full Text] [Related]
12. [A retrospective analysis of the efficacy and safety of imatinib in children with chronic myeloid leukemia during chronic phase].
Zhang LQ; Zheng J; Chen ZP; Li SD; Ma J; Wu RH
Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):113-117. PubMed ID: 30695885
[No Abstract] [Full Text] [Related]
13. Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors.
Yachoui R
Am J Ther; 2014; 21(5):e148-50. PubMed ID: 23567788
[TBL] [Abstract][Full Text] [Related]
14. Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis.
Lopina N; Dyagil I; Hamov D; Zhuravlyova L; Dmytrenko I; Lopin D; Igor K
Cureus; 2018 Aug; 10(8):e3136. PubMed ID: 30345193
[TBL] [Abstract][Full Text] [Related]
15. Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities.
Gareri P; Segura-García C; De Fazio P; De Fazio S; De Sarro G
Ann Pharmacother; 2009 Jul; 43(7):1354-9. PubMed ID: 19567656
[TBL] [Abstract][Full Text] [Related]
16. Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.
Nacif LS; Waisberg DR; Pinheiro RS; Lima FR; Rocha-Santos V; Andraus W; D'Albuquerque LC
J Med Case Rep; 2018 Mar; 12(1):63. PubMed ID: 29523185
[TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
18. Livedoid skin reaction probably due to imatinib therapy.
Martínez-González MC; del Pozo J; Yebra-Pimentel MT; Pérez M; Almagro M; Fonseca E
Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842
[TBL] [Abstract][Full Text] [Related]
19. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Ikuta K; Torimoto Y; Jimbo J; Inamura J; Shindo M; Sato K; Tokusashi Y; Miyokawa N; Kohgo Y
Int J Hematol; 2005 Nov; 82(4):343-6. PubMed ID: 16298828
[TBL] [Abstract][Full Text] [Related]
20. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
